Zoliflodacin

August 24, 2020
I bring new hope for treating an age-old disease.
What molecule am I?

In 2014, Gregory S. Basarab and co-inventors at the AstraZeneca lab in Waltham, MA, filed a US patent application titled “Compounds and Methods for Treating Bacterial Infections”. The compounds of the invention were derivatives of spiro(isoxazolo[4,5-g][oxazino[4,3-a]quinolinepyrimidine)trione. Among the derivatives, there was a compound, AZD0914, that came to be known as zoliflodacin.

The vague title of the application belies its specific purpose: to identify potential drugs to combat multidrug-resistant infectious bacteria. In the background section of the application, the inventors state, “[A]ccording to the Infectious Disease Society of America, methicillin-resistant Staphylococcus aureus (MRSA) kills more Americans every year than emphysema, HIV/AIDS, Parkinson's disease, and homicide combined.” They go on to list several examples of bacteria that had become drug-resistant at the time.

Among the listed bacteria is Neisseria gonorrhoeae, the Gram-negative species that is responsible for the sexually transmitted disease gonorrhea. Zoliflodacin, an inhibitor of DNA gyrase (a subclass of bacterial topoisomerase) is particularly effective for treating this disease. This year, John P. Mueller and co-workers at Entasis Therapeutics (the spinoff from AstraZeneca Waltham) and Antimicrobial Development Specialists (Nyack, NY) published a full report of the development, activity, mode of action, and Phase 1 and 2 clinical trials of zoliflodacin.

The authors also announced the beginning of a Phase 3 trial on ≈1000 subjects this year. The trial is expected to be completed in 2021.

Zoliflodacin hazard information

Hazard class* Hazard statement
Not a hazardous substance or mixture  

 *Globally Harmonized System of Classification and Labeling of Chemicals.

The Molecule of the Week staff thanks the many readers who have sent us suggestions during the past several months. We publish all of the molecules that we think are of interest to our readers—which is to say, almost all of them. If you have a molecule you would like us to consider, please e-mail it to motw@acs.org.

Zoliflodacin fast facts

CAS Reg. No. 1620458-09-4
SciFinder
nomenclature
Spiro(isoxazolo
[4,5-g][1,4]oxazino
[4,3-a]quinoline-5(6H),5′(2′H)-pyrimidine)-2′,4′,6′
(1′H,3′H)-trione, 11-fluoro-1,2,4,4a-tetrahydro-2,4-dimethyl-8-[(4S)-4-methyl-2-oxo-3-oxazolidinyl]-, (2R,4S,4aS)-
Empirical formula C22H22FN5O7
Molar mass 487.44 g/mol
Appearance Solid
Melting point Not reported
Water solubility  0.6 g/L (est.)
Chemical Abstract Service - a division of ACS

Learn more about this molecule from CAS, the most authoritative and comprehensive source for chemical information.

Molecule of the Week needs your suggestions!

If your favorite molecule is not in our archive, please send an email to motw@acs.org. The molecule can be notable for its current or historical importance or for any quirky reason. Thank you!

Stay Ahead of the Chemistry Curve

Learn how ACS can help you stay ahead in the world of chemistry.